Luise Fischer

Aug 7, 2023 | onlinelibrary.wiley.com | Luise Fischer |Nora Grieb |Uwe Platzbecker |Vladan Vucinic

5 EMERGING SPECIFIC SIDE EFFECTS BEYOND CRS AND ICANS As described above, BCMA-targeting CAR T cell therapies are accompanied by cytokine release syndrome (CRS) with very diverse degree of severity, ranging from mild flu-like symptoms up to life-threatening cytokine storm reactions. However, in the vast majority, CRS is manageable with supportive care, steroid treatment, tocilizumab, or other cytokine inhibitors.